Poland· PL-100495020
Chronadamed
A other specific antirheumatic agents product containing chondroitini natrii sulfas + glucosamini sulfas, registered in Poland by Adamed Pharma S.A.. The same ATC class is registered in 3 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Chondroitini natrii sulfas + glucosamini sulfas is registered in 3 of 19 countries.
Countries holding a registration under ATC M01CX (other specific antirheumatic agents), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 3 of them publish a price we can compare per daily dose
Chondroitini natrii sulfas + glucosamini sulfas · ATC M01CX
3 / 19 countries
- Finlandprice
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Chondroitini natrii sulfas + Glucosamini sulfas
- Manufacturer
- Adamed Pharma S.A.
- Country
- Poland (PL)
- ATC code
- M01CX
- ATC class
- Other specific antirheumatic agents
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05900411009447
- gtin05900411011297
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Chondroitini natrii sulfas + glucosamini sulfas in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomBio-Glucosamine MEGA tabletsPharma Nord (UK) Ltd
- SpainDROGLICAN 200 mg/250 mg CAPSULAS DURASLaboratorio Reig Jofre, S.A.
- FinlandDroglicanLaboratorio Reig Jofré, S.A.
- FranceCARTIFIT 200 mg/250 mg, géluleLABORATORIO REIG JOFRE (ESPAGNE)
- NorwayGlucosamine HCl + Chondroitin pure encapPure encapsulations
Authorised across Europe · EMA
The same active substance is authorised in 5 EEA countries. Names it is sold under:
- Austria · Cartifit
- Spain · Droglican
- Finland · Droglican
- France · Cartifit
- Hungary · Droglycan
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/739bac08-d67a-4245-bc62-eb8bb0afc5a3 GET /v1/drugs/739bac08-d67a-4245-bc62-eb8bb0afc5a3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Kapsułki twarde",
"source": "urpl",
"strength": "200 mg + 264,6 mg",
"packaging": "05900411009447 ¦ Rp ¦ 165001\n90 kaps.\n05900411011297 ¦ Rp ¦ 165002\n180 kaps.",
"substance": "Chondroitini natrii sulfas 200 mg + Glucosamini sulfas 264.6 mg",
"common_name": "Chondroitini natrii sulfas + Glucosamini sulfas",
"pl_product_id": "100495020",
"pozwolenie_nr": "29704",
"auth_procedure": "NAR",
"authorisation_validity": "2031-06-30"
}See everything about chondroitini natrii sulfas + glucosamini sulfas.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.